Breaking News Instant updates and real-time market news.

SNAP

Snap

$24.51 /

-7.53 (-23.50%)

04:56
02/04/22
02/04
04:56
02/04/22
04:56

Snap price target lowered to $53 from $72 at Piper Sandler

Piper Sandler analyst Thomas Champion lowered the firm's price target on Snap (SNAP) to $53 from $72 and reiterates an Overweight rating on the shares. The company last night reported a Q4 print with revenue up 43% year-over-year, beating the Street by 9%, Champion tells investors in a research note. Revenue growth fears were "quelled" following a weaker quarter from Meta Planforms (FB) but Apple's (AAPL) Identifier for Advertisers remains a near-term challenge, says the analyst. However, he views Snap's user growth and engagement as solid in a challenging operating environment.

OTHER BREAKING NEWS FROM THE FLY

Conference/Events
OneSpan management to meet with BTIG » 04:55
08/12/22
08/12
04:55
08/12/22
04:55
OSPN

OneSpan

$11.26 /

+0.07 (+0.63%)

Security &…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
OSPN OneSpan
$11.26 /

+0.07 (+0.63%)

OSPN OneSpan
$11.26 /

+0.07 (+0.63%)

02/23/22 DA Davidson
OneSpan price target lowered to $23 from $32 at DA Davidson
OSPN OneSpan
$11.26 /

+0.07 (+0.63%)

Conference/Events
JPMorgan retail analyst to hold analyst/industry conference call » 04:55
08/12/22
08/12
04:55
08/12/22
04:55

Retail/Broadlines &…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Conference/Events
JPMorgan Internet analyst to hold analyst/industry conference call » 04:55
08/12/22
08/12
04:55
08/12/22
04:55

Internet Analyst Anmuth…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

Conference/Events
MercadoLibre participates in a conference call with Susquehanna » 04:55
08/12/22
08/12
04:55
08/12/22
04:55
MELI

MercadoLibre

$1,032.33 /

-32.22 (-3.03%)

FinTech & Payments…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
MELI MercadoLibre
$1,032.33 /

-32.22 (-3.03%)

08/08/22 JPMorgan
MercadoLibre price target raised to $1,350 from $1,300 at JPMorgan
08/04/22 Barclays
MercadoLibre price target lowered to $1,250 from $1,500 at Barclays
08/04/22 Credit Suisse
MercadoLibre price target raised to $1,470 from $1,430 at Credit Suisse
08/01/22 Credit Suisse
MercadoLibre price target lowered to $1,430 from $1,450 at Credit Suisse
MELI MercadoLibre
$1,032.33 /

-32.22 (-3.03%)

  • 16
    Nov
MELI MercadoLibre
$1,032.33 /

-32.22 (-3.03%)

MELI MercadoLibre
$1,032.33 /

-32.22 (-3.03%)

Conference/Events
Seacoast Banking management to meet with Piper Sandler » 04:55
08/12/22
08/12
04:55
08/12/22
04:55
SBCF

Seacoast Banking

$34.73 /

+0.33 (+0.96%)

Meetings to be held in…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SBCF Seacoast Banking
$34.73 /

+0.33 (+0.96%)

SBCF Seacoast Banking
$34.73 /

+0.33 (+0.96%)

08/09/22 Raymond James
Professional Holding downgraded to Market Perform on buyout at Raymond James
07/11/22 B. Riley
Seacoast Banking price target lowered to $34 from $36 at B. Riley
07/06/22 Truist
Seacoast Banking price target lowered to $39 from $42 at Truist
01/17/22 Keefe Bruyette
Seacoast Banking initiated with a Market Perform at Keefe Bruyette
SBCF Seacoast Banking
$34.73 /

+0.33 (+0.96%)

Conference/Events
Piper Sandler US policy heads to hold analyst/industry conference call » 04:55
08/12/22
08/12
04:55
08/12/22
04:55

Head of U.S. Policy…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

Conference/Events
Truist leisure/lodging analyst holds an analyst/industry conference call » 04:55
08/12/22
08/12
04:55
08/12/22
04:55

Lodging Analysts discuss…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

Conference/Events
Live Oak Bancshares participates in a conference call with Truist » 04:55
08/12/22
08/12
04:55
08/12/22
04:55
LOB

Live Oak Bancshares

$41.36 /

+0.76 (+1.87%)

Analysts Demba and King…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
LOB Live Oak Bancshares
$41.36 /

+0.76 (+1.87%)

LOB Live Oak Bancshares
$41.36 /

+0.76 (+1.87%)

07/07/22 Raymond James
Live Oak Bancshares downgraded to Market Perform at Raymond James
07/07/22 Raymond James
Live Oak Bancshares downgraded to Market Perform from Outperform at Raymond James
07/01/22 JPMorgan
Live Oak Bancshares downgraded to Neutral from Overweight at JPMorgan
06/29/22 Piper Sandler
Live Oak Bancshares price target lowered to $40 from $51 at Piper Sandler
LOB Live Oak Bancshares
$41.36 /

+0.76 (+1.87%)

General news
European stock markets are broadly higher » 04:35
08/12/22
08/12
04:35
08/12/22
04:35
$ECON

Economic Data

/

+

European stock markets…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

General news
Market Update: » 02:40
08/12/22
08/12
02:40
08/12/22
02:40
$ECON

Economic Data

/

+

Market Update: Stocks in…

Market Update: Stocks in Japan rallied in catch up trade on their return from yesterday's holiday, but elsewhere the picture looked patchy overnight. The ASX lost -0.5% and Hang Seng and CSI 300 are up 0.37% and down -0.06% respectively, after a narrowly mixed close on Wall Street. European and U.S. futures are posting modest gains though. Treasury yields corrected -1.8 bp to 2.87%, but the curve inverted further as the short end underperformed also thanks to comments from Fed's Daly who told Bloomberg yesterday, that there is an improvement in inflaiton numbers, but victory, repeating that her base case is for a half-percentage point hike at the next meeting. Markets seem to be rethinking the global rate outlook and yields in Australia and to a lesser extend New Zealand backed up today. Bunds are also underperforming versus Treasuries in early trade, and the 10-year rate is up 2.1 bp at 0.987%. In FX markets the DXY dollar index lifted to 105.141, but is still heading for a weekly loss amid trimmed back expectations for the Fed's tightening path. The front end WTI future meanwhile is at USD 93.90, Brent at USD 99.22 per barrel, after the IEA upgraded its demand outlook yesterday.

ShowHide Related Items >><<
$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

Recommendations
Apyx Medical price target raised to $12 from $6 at Piper Sandler » 20:54
08/11/22
08/11
20:54
08/11/22
20:54
APYX

Apyx Medical

$10.34 /

-0.51 (-4.70%)

Piper Sandler analyst…

Piper Sandler analyst Matt O'Brien raised the firm's price target on Apyx Medical to $12 from $6 and keeps an Overweight rating on the shares. The company's Q2 revenue missed expectations due to greater-than-expected demand impacts within the Advanced Energy business from the FDA safety communication in March, though next year is setting up for an acceleration in the business, with mid-teens growth expected through FY25, the analyst tells investors in a research note.

ShowHide Related Items >><<
APYX Apyx Medical
$10.34 /

-0.51 (-4.70%)

APYX Apyx Medical
$10.34 /

-0.51 (-4.70%)

07/19/22 Lake Street
Apyx Medical price target raised to $17 from $14 at Lake Street
07/18/22 Piper Sandler
Apyx Medical FDA clearance should help reaccelerate growth, says Piper Sandler
07/11/22 Lake Street
Apyx Medical price target raised to $14 from $12 at Lake Street
05/26/22 Piper Sandler
Piper says Apyx Medical label expansion 'positive on a couple of levels'
APYX Apyx Medical
$10.34 /

-0.51 (-4.70%)

Recommendations
Sight Sciences price target lowered to $15 from $17 at Piper Sandler » 20:46
08/11/22
08/11
20:46
08/11/22
20:46
SGHT

Sight Sciences

$9.84 /

-0.29 (-2.86%)

Piper Sandler analyst…

Piper Sandler analyst Matt O'Brien lowered the firm's price target on Sight Sciences to $15 from $17 after its Q2 earnings miss as he adjusts his valuation model with unchanged 6-times enterprise value to expected FY23 sales multiple but keeps an Overweight rating on the shares. The analyst still believes that Sight Sciences management is building a strong franchise that will generate sizable levels of sales and eventually profitability.

ShowHide Related Items >><<
SGHT Sight Sciences
$9.84 /

-0.29 (-2.86%)

SGHT Sight Sciences
$9.84 /

-0.29 (-2.86%)

07/25/22 Stifel
Sight Sciences initiated with a Hold at Stifel
05/11/22 Piper Sandler
Sight Sciences price target lowered to $17 from $23 at Piper Sandler
04/19/22 Piper Sandler
Piper Sandler continues to recommend exposure to medtech space after J&J results
03/25/22 Citi
Sight Sciences price target lowered to $35 from $39 at Citi
SGHT Sight Sciences
$9.84 /

-0.29 (-2.86%)

SGHT Sight Sciences
$9.84 /

-0.29 (-2.86%)

SGHT Sight Sciences
$9.84 /

-0.29 (-2.86%)

Earnings
ProFrac Holding reports Q2 adjusted EBITDA $210.6M vs. $34.1M last year » 20:28
08/11/22
08/11
20:28
08/11/22
20:28
PFHC

ProFrac Holding

$18.24 /

+0.44 (+2.47%)

Reports Q2 revenue…

Reports Q2 revenue $589.8M, consensus $569.4M. The company states: "The Company is deploying its first electric fleet during the third quarter and expects to average approximately 31 active fleets for the full quarter. We expect to deploy two more electric fleets in the fourth quarter. There are no current plans to reactivate any conventional or dual fuel fleets for the remainder of 2022. The Company also expects incremental improvement in third quarter results, as compared to the second quarter attributable to further bundling of materials with our pressure pumping services, continued pricing improvements, and the anticipated deployment of our first electric fleet."

ShowHide Related Items >><<
PFHC ProFrac Holding
$18.24 /

+0.44 (+2.47%)

PFHC ProFrac Holding
$18.24 /

+0.44 (+2.47%)

07/15/22 BofA
ProFrac Holding downgraded to Neutral from Buy at BofA
07/13/22 Morgan Stanley
ProFrac Holding price target lowered to $28 from $30 at Morgan Stanley
06/22/22 Johnson Rice
ProFrac Holding initiated with a Buy at Johnson Rice
06/21/22 Stifel
ProFrac Holding price target raised to $27 from $24 at Stifel
  • 13
    May
PFHC ProFrac Holding
$18.24 /

+0.44 (+2.47%)

PFHC ProFrac Holding
$18.24 /

+0.44 (+2.47%)

Hot Stocks
Offerpad Solutions director buys $1.69M in common stock » 20:13
08/11/22
08/11
20:13
08/11/22
20:13
OPAD

Offerpad Solutions

$1.70 /

-0.005 (-0.29%)

In a regulatory filing,…

In a regulatory filing, Offerpad Solutions disclosed that its director Roberto Sella bought 1M shares of common stock on August 9th in a total transaction size of $1.69M.

ShowHide Related Items >><<
OPAD Offerpad Solutions
$1.70 /

-0.005 (-0.29%)

OPAD Offerpad Solutions
$1.70 /

-0.005 (-0.29%)

08/04/22 Cantor Fitzgerald
Offerpad Solutions price target lowered to $5 from $10 at Cantor Fitzgerald
07/22/22 Cantor Fitzgerald
Offerpad Solutions assumed with an Overweight at Cantor Fitzgerald
07/11/22 Wedbush
Offerpad Solutions initiated with an Outperform at Wedbush
07/11/22 Wedbush
Offerpad Solutions initiated with an Outperform at Wedbush
OPAD Offerpad Solutions
$1.70 /

-0.005 (-0.29%)

OPAD Offerpad Solutions
$1.70 /

-0.005 (-0.29%)

OPAD Offerpad Solutions
$1.70 /

-0.005 (-0.29%)

OPAD Offerpad Solutions
$1.70 /

-0.005 (-0.29%)

Hot Stocks
Cathie Wood's ARK Investment bought 628K shares of Fate Therapeutics today  20:10
08/11/22
08/11
20:10
08/11/22
20:10
FATE

Fate Therapeutics

$32.68 /

+0.26 (+0.80%)

 
ShowHide Related Items >><<
FATE Fate Therapeutics
$32.68 /

+0.26 (+0.80%)

FATE Fate Therapeutics
$32.68 /

+0.26 (+0.80%)

08/04/22 Oppenheimer
Fate Therapeutics price target lowered to $90 from $135 at Oppenheimer
07/28/22 Needham
Fate Therapeutics initiated with a Hold at Needham
07/11/22 BMO Capital
Fate Therapeutics upgraded to Outperform from Market Perform at BMO Capital
06/03/22 Baird
Baird starts Fate Therapeutics at Neutral with limited data on NK cell therapies
FATE Fate Therapeutics
$32.68 /

+0.26 (+0.80%)

FATE Fate Therapeutics
$32.68 /

+0.26 (+0.80%)

Hot Stocks
Cathie Wood's ARK Investment bought 101K shares of Teladoc today  20:09
08/11/22
08/11
20:09
08/11/22
20:09
TDOC

Teladoc

$37.98 /

+0.21 (+0.56%)

 
ShowHide Related Items >><<
TDOC Teladoc
$37.98 /

+0.21 (+0.56%)

TDOC Teladoc
$37.98 /

+0.21 (+0.56%)

08/11/22 DA Davidson
Teladoc initiated with a Buy at DA Davidson
08/02/22 Berenberg
Berenberg downgrades Teladoc to Hold on 'underwhelming execution'
08/02/22 Cowen
Teladoc downgraded to Market Perform from Outperform at Cowen
07/29/22 Deutsche Bank
Teladoc price target lowered to $34 from $44 at Deutsche Bank
TDOC Teladoc
$37.98 /

+0.21 (+0.56%)

TDOC Teladoc
$37.98 /

+0.21 (+0.56%)

TDOC Teladoc
$37.98 /

+0.21 (+0.56%)

TDOC Teladoc
$37.98 /

+0.21 (+0.56%)

Syndicate
Corphousing prices 3.375M share IPO at $4.00 » 20:02
08/11/22
08/11
20:02
08/11/22
20:02
CHG

Corphousing

/

+

Maxim Group LLC is acting…

Maxim Group LLC is acting as the lead book-running manager in connection with the offering and Joseph Gunnar & Co. is acting as joint book-running manager for the offering.

ShowHide Related Items >><<
  • 12
    Aug
Syndicate
Portillo's 8M share Secondary priced at $23.75 » 19:57
08/11/22
08/11
19:57
08/11/22
19:57
PTLO

Portillo's

$25.02 /

-0.985 (-3.79%)

The deal priced below…

The deal priced below last closing price of $24.97. Jefferies and Morgan Stanley are acting as joint book running managers for the offering.

ShowHide Related Items >><<
PTLO Portillo's
$25.02 /

-0.985 (-3.79%)

PTLO Portillo's
$25.02 /

-0.985 (-3.79%)

08/05/22 Baird
Portillo's price target raised to $30 from $22 at Baird
08/05/22 Piper Sandler
Portillo's price target raised to $27 from $23 at Piper Sandler
06/28/22 Morgan Stanley
Portillo's initiated with an Equal Weight at Morgan Stanley
06/08/22
Baird to hold a conference
PTLO Portillo's
$25.02 /

-0.985 (-3.79%)

  • 12
    Aug
  • 21
    Oct
PTLO Portillo's
$25.02 /

-0.985 (-3.79%)

PTLO Portillo's
$25.02 /

-0.985 (-3.79%)

Syndicate
Reborn Coffee 1.44M share IPO priced at $5.00 » 19:49
08/11/22
08/11
19:49
08/11/22
19:49
REBN

Reborn Coffee

/

+

The deal size was…

The deal size was increased to $7.2M from $6.0M. EF Hutton is acting as sole book running manager for the offering.

ShowHide Related Items >><<
  • 12
    Aug
REBN Reborn Coffee
/

+

General news
Fed President Mary Daly says workers looking for jobs now do not see recession » 19:46
08/11/22
08/11
19:46
08/11/22
19:46
SPY

SPDR S&P 500 ETF Trust

$420.01 /

+0.06 (+0.01%)

, SPX

S&P 500

/

+

, QQQ

Invesco QQQ Trust

$324.08 /

-1.84 (-0.56%)

Says long way from…

Says long way from evaluating risks of not pulling back on tightening; Says the main risk in the economy is that inflation is too high; Says another tightening of 50bps makes sense to me right now, but have open mind on 75bps hike in September. Says looking at job openings and quit rate in addition to unemployment rate; Says will take some time for home rental inflation to level off; Says if services inflation continues to rise, we still have a lot of work to do; Says about 100bps increase before the end of 2022 looks right for now; Says will raise rates to a level appropriate and then hold them there for a while. Comments from Bloomberg TV interview.

ShowHide Related Items >><<
SPY SPDR S&P 500 ETF Trust
$420.01 /

+0.06 (+0.01%)

QQQ Invesco QQQ Trust
$324.08 /

-1.84 (-0.56%)

SPY SPDR S&P 500 ETF Trust
$420.01 /

+0.06 (+0.01%)

07/25/22 JPMorgan
JPMorgan strategist says mild recession already priced in
07/13/22 Nomura
Nomura expects 100 point rate hike in July after June CPI data
07/01/22 JPMorgan
JPMorgan forecast 'perilously close' to recession after GDP cuts
06/27/22 Citi
Citi cuts S&P 500 year-end target, sees positive second half setup
SPX S&P 500
/

+

QQQ Invesco QQQ Trust
$324.08 /

-1.84 (-0.56%)

04/25/22 Gordon Haskett
Twitter bid more attractive after market selloff, says Gordon Haskett
SPY SPDR S&P 500 ETF Trust
$420.01 /

+0.06 (+0.01%)

SPY SPDR S&P 500 ETF Trust
$420.01 /

+0.06 (+0.01%)

SPY SPDR S&P 500 ETF Trust
$420.01 /

+0.06 (+0.01%)

QQQ Invesco QQQ Trust
$324.08 /

-1.84 (-0.56%)

SPX S&P 500
/

+

SPY SPDR S&P 500 ETF Trust
$420.01 /

+0.06 (+0.01%)

SPX S&P 500
/

+

QQQ Invesco QQQ Trust
$324.08 /

-1.84 (-0.56%)

Earnings
4D Molecular reports Q2 EPS (87c), consensus (85c) » 19:06
08/11/22
08/11
19:06
08/11/22
19:06
FDMT

4D Molecular

$10.37 /

-0.27 (-2.54%)

"Maintaining our…

"Maintaining our momentum from the first quarter, we continued to execute towards our clinical and corporate milestones, including progress across all of our five clinical-stage product candidates," said David Kirn, M.D., Co-founder, President and Chief Executive Officer of 4DMT. "In addition, the protocol amendment for the 4D-310 Phase 1/2 clinical trial in Fabry disease will expand access to include female patients, a large and significantly affected patient population with Fabry disease. We have maintained our focus on efficient cash utilization, with current cash available to support our operations into the first half of 2025. Our team is committed to relentless execution as we make progress toward key clinical data readouts in the first half of 2023 and beyond."

ShowHide Related Items >><<
FDMT 4D Molecular
$10.37 /

-0.27 (-2.54%)

FDMT 4D Molecular
$10.37 /

-0.27 (-2.54%)

06/22/22 Jefferies
4D Molecular initiated with a Buy at Jefferies
06/13/22 Wedbush
Sangamo assumed with a Neutral, $5 price target at Wedbush
01/04/22 SVB Securities
SVB Leerink bullish on 4D Molecular, initiates with an Outperform
01/04/22 SVB Securities
4D Molecular initiated with an Outperform at SVB Leerink
FDMT 4D Molecular
$10.37 /

-0.27 (-2.54%)

  • 29
    Oct
FDMT 4D Molecular
$10.37 /

-0.27 (-2.54%)

Earnings
PureCycle Technologies reports Q2 EPS (9c), consensus (14c) » 19:04
08/11/22
08/11
19:04
08/11/22
19:04
PCT

PureCycle Technologies

$9.47 /

+0.215 (+2.32%)

The company states:…

The company states: "To date, we have not generated any operating revenue. We expect to begin to generate revenue in 2023 from our commercial plant and PreP facilities."

ShowHide Related Items >><<
PCT PureCycle Technologies
$9.47 /

+0.215 (+2.32%)

PCT PureCycle Technologies
$9.47 /

+0.215 (+2.32%)

03/10/22 Craig-Hallum
PureCycle Technologies price target lowered to $18 from $26 at Craig-Hallum
03/10/22 Oppenheimer
PureCycle Technologies price target lowered to $16 from $28 at Oppenheimer
11/12/21 Craig-Hallum
PureCycle Technologies price target lowered to $26 from $48 at Craig-Hallum
09/23/21 Cowen
PureCycle Technologies initiated with an Outperform at Cowen
PCT PureCycle Technologies
$9.47 /

+0.215 (+2.32%)

PCT PureCycle Technologies
$9.47 /

+0.215 (+2.32%)

Earnings
Kinnate Biopharma reports Q2 EPS (62c), consensus (64c) » 18:59
08/11/22
08/11
18:59
08/11/22
18:59
KNTE

Kinnate Biopharma

$13.33 /

-1.47 (-9.93%)

"Kinnate is making…

"Kinnate is making meaningful progress with its proprietary clinical and preclinical precision oncology programs," said Nima Farzan, chief executive officer, Kinnate Biopharma Inc. "We continue to expand the global footprint of clinical trial sites for our pan-RAF inhibitor, KIN-2787, for which we expect to share initial clinical data later this year. The Kinnate Discovery Engine is actively generating new research leads, and with our financial strength, we're well positioned to invest in breakthrough science and long-term growth of the company."

ShowHide Related Items >><<
KNTE Kinnate Biopharma
$13.33 /

-1.47 (-9.93%)

KNTE Kinnate Biopharma
$13.33 /

-1.47 (-9.93%)

07/28/22 H.C. Wainwright
Kinnate Biopharma initiated with a Buy at H.C. Wainwright
06/03/22 Wedbush
Wedbush downgrades Turning Point, says deal positive for small/mid-cap biotechs
05/18/22 Piper Sandler
Kinnate Biopharma price target lowered to $30 from $52 at Piper Sandler
01/07/22 Wedbush
Kinnate Biopharma price target lowered to $44 from $53 at Wedbush
KNTE Kinnate Biopharma
$13.33 /

-1.47 (-9.93%)

Syndicate
Silence Therapeutics prices 5.95M ADSs at $9.50 per share » 18:58
08/11/22
08/11
18:58
08/11/22
18:58
SLN

Silence Therapeutics

$9.95 /

+0.075 (+0.76%)

Silence intends to use…

Silence intends to use the net proceeds of the offering, together with its existing cash and cash equivalents to fund the advancement of its clinical trials, including its Phase 2 trial of SLN360 in ASCVD and its Phase 1/2 trial of SLN124 in polycythemia vera, as well as expansion of pipeline programs, working capital and general corporate purposes. Morgan Stanley and William Blair are acting as joint book-running managers for the offering.

ShowHide Related Items >><<
SLN Silence Therapeutics
$9.95 /

+0.075 (+0.76%)

SLN Silence Therapeutics
$9.95 /

+0.075 (+0.76%)

03/31/22 Chardan
Silence Therapeutics initiated with a Buy at Chardan
03/22/22 H.C. Wainwright
Silence Therapeutics price target lowered to $95 from $100 at H.C. Wainwright
Hot Stocks
T-Mobile exec sells $7.26M in common stock » 18:48
08/11/22
08/11
18:48
08/11/22
18:48
TMUS

T-Mobile

$143.57 /

-1.13 (-0.78%)

In a regulatory filing,…

In a regulatory filing, T-Mobile disclosed that its Technology President Nevilled Ray sold 50K shares of common stock on August 9th in a total transaction size of $7.26M.

ShowHide Related Items >><<
TMUS T-Mobile
$143.57 /

-1.13 (-0.78%)

TMUS T-Mobile
$143.57 /

-1.13 (-0.78%)

07/28/22 Cowen
T-Mobile price target raised to $187 from $179 at Cowen
07/28/22 Barclays
T-Mobile price target raised to $160 from $150 at Barclays
07/28/22 Scotiabank
T-Mobile upgraded to Outperform at Scotiabank on outgrowth over peers
07/28/22 Scotiabank
T-Mobile upgraded to Outperform from Sector Perform at Scotiabank
TMUS T-Mobile
$143.57 /

-1.13 (-0.78%)

  • 09
    Sep
TMUS T-Mobile
$143.57 /

-1.13 (-0.78%)

TMUS T-Mobile
$143.57 /

-1.13 (-0.78%)

TMUS T-Mobile
$143.57 /

-1.13 (-0.78%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.